pharma whats-next-drug-pricing-2023 
pharmaphorum
DECEMBER 15, 2022
A pharma industry organisation has warned that record levels of revenue clawback from the UK government is threatening “footprint, R&D and manufacturing investments” in the country. of total sales – under the Voluntary Scheme for Branded Medicines Pricing and Access (VPAS) introduced in 2019. VPAS tax on top. .
Viseven
JUNE 12, 2023
In this article, we’ll focus on a pharmaceutical market in the APAC region, go through the differences between pharma in APAC and pharma in other parts of the world, and see the current state of the APAC pharma market. This role is significant because the pharma market in APAC is increasing. from 2022 to 2027.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
MAY 2, 2023
In 2019, the pharmaceutical industry spent $83 billion on R&D, which is about 10 times what the industry spent per year in the 1980s, 4 yet the average duration to develop a new medicine is still around 10-15 years. 7 While this context is well known, we are yet to fully realise what an ideal R&D future looks like.
ISPE
MAY 10, 2023
What do you see for the future of manufacturing? The current healthcare landscape is influenced by a lot of micro and macro trends, such as shorter innovation cycles, price reform, access expansion, and patient engagement. Patients should benefit from having more accessibility to more affordable drugs.
Pharmaceutical Technology
OCTOBER 5, 2022
Technology is advancing the possibilities of healthcare treatments, from the development of innovative new drugs to freeing up time for doctors thanks to monitoring devices for patients with conditions such as diabetes and high blood pressure. However, this is not typically the case in the UK health and pharma segments.
PharmaShots
MARCH 30, 2023
Morgan Health Care Conference 2023 The interview depicts MedVector’s approach to empower clinical trial sites to efficiently gain access to more qualified clinical trial participants through treating physicians Smriti: To start, could you please provide a brief bio to our readers about MedVector?
ISPE
JULY 6, 2023
ICH Q13 and What Is Next for Continuous Manufacturing Trudy Patterson Thu, 07/06/2023 - 06:51 Features July / August 2023 ICH Q13 and What Is Next for Continuous Manufacturing Gabriella Dahlgren, PhD Douglas B. Published July 2021. Q13 generated significant interest.
Expert insights. Personalized for you.
70 
Let's personalize your content